The role of intravitreal ranubizumab in the treatment of familial exudative vitreoretinopathy of stage 2 or greater
AIM: To evaluate the role of intravitreal ranubizumab (IVR) in the treatment of familial exudative vitreoretinopathy (FEVR) of stage 2 or greater either as primary or an ajunct to conventional treatments. METHODS: Retrospective, non-controlled clinical study. Thirty patients (37 eyes) diagnosed wit...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Press of International Journal of Ophthalmology (IJO PRESS)
2018-06-01
|
| Series: | International Journal of Ophthalmology |
| Subjects: | |
| Online Access: | http://www.ijo.cn/en_publish/2018/6/20180613.pdf |
| _version_ | 1817990441118728192 |
|---|---|
| author | Yue-Zhu Lu Guang-Da Deng Jing-Hua Liu Hong Yan |
| author_facet | Yue-Zhu Lu Guang-Da Deng Jing-Hua Liu Hong Yan |
| author_sort | Yue-Zhu Lu |
| collection | DOAJ |
| description | AIM: To evaluate the role of intravitreal ranubizumab (IVR) in the treatment of familial exudative vitreoretinopathy (FEVR) of stage 2 or greater either as primary or an ajunct to conventional treatments.
METHODS: Retrospective, non-controlled clinical study. Thirty patients (37 eyes) diagnosed with FEVR were enrolled. Twenty patients (66.67%) were male and 10 patients (33.33%) were female. Age ranged from 0.4 to 35 years old (median 3y). IVR was used either as primary or as a combined therapy according to the retinal neovasuclar activities. The follow up ranged from 1 to 57mo with mean 16.73±15.73 (median 11)mo. The treatment effect of retinal neovasuclar activites were recorded as well as the ocular and systemic side effects.
RESULTS: Among 30 patients (37 eyes), 10 eyes received single IVR, 1 eye received 2 injections. Three eyes were treated with IVR and simutanous laser photocoagulation. Laser indirect ophthalmoscopy (LIO) was applied in 5 eyes 1mo after the primary IVR. Seven eyes were treated surgically following the primary IVR due to persistent retinal neovasuclar activities and retinal traction. IVR was used as combined treatment with vitrectomy in 11 eyes. Retinal neovascular regression was notified 1mo following the primary IVR in all eyes. Neither systemic nor ocular complications were recorded.
CONCLUSION: IVR may be an effective modality in the treatment of FEVR either as primary or as an ajunct to the conventional therapies. The long term effect and safty of IVR still need further research. |
| first_indexed | 2024-04-14T01:00:13Z |
| format | Article |
| id | doaj.art-1e9f8c0126244dad9914f62434fcf981 |
| institution | Directory Open Access Journal |
| issn | 2222-3959 2227-4898 |
| language | English |
| last_indexed | 2024-04-14T01:00:13Z |
| publishDate | 2018-06-01 |
| publisher | Press of International Journal of Ophthalmology (IJO PRESS) |
| record_format | Article |
| series | International Journal of Ophthalmology |
| spelling | doaj.art-1e9f8c0126244dad9914f62434fcf9812022-12-22T02:21:27ZengPress of International Journal of Ophthalmology (IJO PRESS)International Journal of Ophthalmology2222-39592227-48982018-06-0111697698010.18240/ijo.2018.06.13The role of intravitreal ranubizumab in the treatment of familial exudative vitreoretinopathy of stage 2 or greaterYue-Zhu Lu0Guang-Da Deng1Jing-Hua Liu2Hong Yan3The First Clinical College of Chongqing Medical University, Chongqing 400016, ChinaDepartment of Opthalmology, Beijing Tongren Hospital, Capital University of Medical Sience, Beijing 100730, ChinaDepartment of Opthalmology, Beijing Tongren Hospital, Capital University of Medical Sience, Beijing 100730, ChinaDepartment of Ophthalmology, the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, ChinaAIM: To evaluate the role of intravitreal ranubizumab (IVR) in the treatment of familial exudative vitreoretinopathy (FEVR) of stage 2 or greater either as primary or an ajunct to conventional treatments. METHODS: Retrospective, non-controlled clinical study. Thirty patients (37 eyes) diagnosed with FEVR were enrolled. Twenty patients (66.67%) were male and 10 patients (33.33%) were female. Age ranged from 0.4 to 35 years old (median 3y). IVR was used either as primary or as a combined therapy according to the retinal neovasuclar activities. The follow up ranged from 1 to 57mo with mean 16.73±15.73 (median 11)mo. The treatment effect of retinal neovasuclar activites were recorded as well as the ocular and systemic side effects. RESULTS: Among 30 patients (37 eyes), 10 eyes received single IVR, 1 eye received 2 injections. Three eyes were treated with IVR and simutanous laser photocoagulation. Laser indirect ophthalmoscopy (LIO) was applied in 5 eyes 1mo after the primary IVR. Seven eyes were treated surgically following the primary IVR due to persistent retinal neovasuclar activities and retinal traction. IVR was used as combined treatment with vitrectomy in 11 eyes. Retinal neovascular regression was notified 1mo following the primary IVR in all eyes. Neither systemic nor ocular complications were recorded. CONCLUSION: IVR may be an effective modality in the treatment of FEVR either as primary or as an ajunct to the conventional therapies. The long term effect and safty of IVR still need further research.http://www.ijo.cn/en_publish/2018/6/20180613.pdf980familial exudative vitreoretinopathyanti-vascular endothelial growth factortreatment |
| spellingShingle | Yue-Zhu Lu Guang-Da Deng Jing-Hua Liu Hong Yan The role of intravitreal ranubizumab in the treatment of familial exudative vitreoretinopathy of stage 2 or greater International Journal of Ophthalmology 980 familial exudative vitreoretinopathy anti-vascular endothelial growth factor treatment |
| title | The role of intravitreal ranubizumab in the treatment of familial exudative vitreoretinopathy of stage 2 or greater |
| title_full | The role of intravitreal ranubizumab in the treatment of familial exudative vitreoretinopathy of stage 2 or greater |
| title_fullStr | The role of intravitreal ranubizumab in the treatment of familial exudative vitreoretinopathy of stage 2 or greater |
| title_full_unstemmed | The role of intravitreal ranubizumab in the treatment of familial exudative vitreoretinopathy of stage 2 or greater |
| title_short | The role of intravitreal ranubizumab in the treatment of familial exudative vitreoretinopathy of stage 2 or greater |
| title_sort | role of intravitreal ranubizumab in the treatment of familial exudative vitreoretinopathy of stage 2 or greater |
| topic | 980 familial exudative vitreoretinopathy anti-vascular endothelial growth factor treatment |
| url | http://www.ijo.cn/en_publish/2018/6/20180613.pdf |
| work_keys_str_mv | AT yuezhulu theroleofintravitrealranubizumabinthetreatmentoffamilialexudativevitreoretinopathyofstage2orgreater AT guangdadeng theroleofintravitrealranubizumabinthetreatmentoffamilialexudativevitreoretinopathyofstage2orgreater AT jinghualiu theroleofintravitrealranubizumabinthetreatmentoffamilialexudativevitreoretinopathyofstage2orgreater AT hongyan theroleofintravitrealranubizumabinthetreatmentoffamilialexudativevitreoretinopathyofstage2orgreater AT yuezhulu roleofintravitrealranubizumabinthetreatmentoffamilialexudativevitreoretinopathyofstage2orgreater AT guangdadeng roleofintravitrealranubizumabinthetreatmentoffamilialexudativevitreoretinopathyofstage2orgreater AT jinghualiu roleofintravitrealranubizumabinthetreatmentoffamilialexudativevitreoretinopathyofstage2orgreater AT hongyan roleofintravitrealranubizumabinthetreatmentoffamilialexudativevitreoretinopathyofstage2orgreater |